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Myxomatous mitral valve disease (MMVD) is the most common heart disease of dogs. The 
current management of MMVD in dogs is mostly pharmacological, and the recommendations 
for  treatment  are  based  on  a  number  of  veterinary  studies.  Notwithstanding  the  current 
consensus  regarding  the  medical  management  of  MMVD,  there  remains  active  debate 
as to which drugs are the most effective. In order to understand how recommendations 
are constructed in the pharmacological management of diseases, the veterinarian needs to 
understand the concept of evidence-based veterinary medicine, and how the findings of these 
studies can be applied in their own practices. This review summarises the current veterinary 
literature and explains how the consensus regarding the management of MMVD has been 
reached.  This  review  highlights  the  limitations  of  veterinary  studies  in  order  to  provide 
veterinary practitioners with a sense of the difficulty there is in establishing the benefit of one 
treatment over the other. Veterinarians should therefore apply treatment recommendations 
based on the best evidence, integrated with a pathomechanistic understanding of the disease 
process and clinical experience.
Introduction
The growing popularity of evidence-based medicine (EBM) has transformed the way clinical 
trials are performed and, indeed, their interpretation (Cockcroft & Holmes 2003; Geyman 2000; 
Hjørland 2011; Sackett, Straus & Richardson 2000). The notion of EBM is born out of the observation 
that clinical observations are prone to bias and that natural variations in clinical outcome of a 
disease course may be wrongfully attributed to a treatment intervention (Hjørland 2011). Medical 
practices, whilst firmly based on pure sciences, have retained an element of their artistic origins, 
with the result that hypothesis-driven research in clinical practice is a relatively new concept 
(Hjørland 2011). The opinion of experts and clinical experience are still heavily weighted in the 
clinical realm and a clinician is an individual who draws on many resources to ultimately tailor 
a clinical treatment for an individual patient. Whilst the role of the clinician’s own experience 
and expertise cannot be undervalued, the observations of the physician, when contrasted with 
pathomechanistically rationalised treatments, are extremely prone to bias. Hence, with regard to 
‘strength of evidence’, the opinion of experts is seen as the weakest grade of evidence (Hjørland 
2011). The philosopher Karl Popper promoted the idea of conjecture and refutation, which states 
that a scientific experiment should seek to disprove a hypothesis, and that failure to do so would 
result in the adoption of an alternate hypothesis (Popper 1963). This thought process attempts 
to force researchers to conscientiously refute their own theories, and only to accept them if they 
are unable to do so. It becomes apparent, therefore, that clinical trials have to be designed to 
remove the human element of bias and thus prospective, randomised, blinded clinical trials 
are considered to yield the best grade of evidence (Hjørland 2011). As with any new paradigm, 
proselytes quickly accrue. This has certainly been the case with EBM, with a new generation of 
veterinarians and residents who have become EBM zealots to the point that they are hesitant to 
adopt any medical practice that cannot be backed up with a paper, thus discarding one of the 
greatest attributes of the clinician, namely experience and clinical intuition. Those subscribing 
to a purist EBM approach alone should be reminded of the maxim ‘absence of evidence is not 
evidence of absence’.1 Recommendations based on EBM, which is a sound practice, should be 
integrated with clinical experience and individual patient appraisal to achieve the best clinical 
treatment. Understanding the basis and context of EBM will help veterinarians understand why 
certain publications are given more weight than others in the development of recommendations, 
which is particularly true in the case of angiotensin-converting enzyme (ACE) inhibitors (ACEIs). 
Using the grading of evidence paradigm (Table 1), if grade 1 evidence is available it will generally 
override contrary evidence of a lower grade.
1.Attributed to cosmologist Martin Rees.
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Randomised  clinical  trials  (RCTs)  that  are  blinded  are 
considered  the  best  grade  of  evidence.  In  the  case  of 
myxomatous  mitral  valve  disease  (MMVD),  the  benign 
nature of the disease in terms of progression and the natural 
variation in clinical presentation and outcome complicates 
the  design  of  RCTs  and  increases  the  expense.  Firstly, 
patients need to be classified according to a heart failure 
stage (Figure 1), which presents a challenge, as the onset of 
heart failure is gradual and multifactorial and by definition 
a  continuous  variable,  which  is  categorised  as  an  ordinal 
variable.
Figure  1  provides  a  diagrammatic  representation  of  how 
a heart failure staging system seeks to categorise patients 
according to the severity of heart failure. The blocks with 
the associated letters represent the current stages according 
to  the  American  College  of  Veterinary  Internal  Medicine 
(ACVIM) consensus statement (Atkins et al. 2009). A staging 
system  represents  an  ordinal  variable  which  assigns  a 
diverse group of patients to a finite, predetermined, limited 
number of categories. The actual progression of congestive 
heart failure (CHF) is conceptually shown by the colour bar, 
which represents the progression as a continuous variable. 
On the basis of this diagram it can be appreciated that even 
within each category there is considerable variation between 
the individuals.
Secondly,  because  MMVD  progresses  slowly  and  the 
numbers  of  patients  who  deteriorate  is  not  very  high 
(Borgarelli  et  al.  2012),  RCTs  need  to  be  conducted 
over  a  long  period  and  with  many  patients  per  group. 
Notwithstanding these limitations, several RCTs published 
in  the  last  18  years  have  formed  the  basis  of  MMVD 
treatment  recommendations.  There  are  eight  RCTs  that 
have investigated the use of ACEIs in MMVD and two that 
have assessed the efficacy of pimobendan in the treatment of 
MMVD. One RCT trial was conducted using spironolactone 
in the management of MMVD (see below).
In addition to a blinded RCT, experimental and mechanistic 
studies have also contributed to the understanding of the 
action and efficacy of cardiovascular drugs. Several studies 
have  investigated  the  effects  of  cardiovascular  drugs  on 
echocardiographic parameters. Conceptually, if a drug has 
a beneficial or deleterious effect, then an improvement or 
worsening would be expected in certain echocardiographic 
parameters. Of interest are the studies pertaining to ACEI 
and  pimobendan,  as  this  remains  a  controversial  issue. 
The  reader  should  understand  that  at  the  heart  of  the 
pimobendan/ACEI  debate  is  the  battle  for  supremacy  in 
the treatment of MMVD between proponents of these two 
drugs.  It  may  seem  a  spurious  comparison  to  the  astute 
reader given the divergent mechanisms of action of the two 
drugs, and it would seem wiser to include both drugs in 
various treatment regimens. Notwithstanding the apparent 
wisdom of this view, vehement debate still exists as to the 
touted  benefits  of  pimobendan  in  MMVD.  Of  particular 
interest  to  the  reader  would  be  that  there  is  currently  no 
evidence demonstrating synergistic benefit or adverse effects 
of pimobendan combined with an ACEI. In an experimental 
study in 12 beagles with experimentally induced MMVD, 
pimobendan was shown to have adverse effects on selected 
echocardiographic  parameters  and  was  associated  with 
more severe mitral valve lesions on postmortem examination 
compared with an ACEI (Chetboul et al. 2007). This study was 
performed in asymptomatic dogs and the authors concluded 
that  pimobendan  should  be  assessed  in  symptomatic 
MMVD. Critics of this study (Corcoran et al. 2008) pointed 
out  that  the  assessment  of  cardiac  function  (based  on 
echocardiography) was flawed in this study. Furthermore, 
they  contended  that  the  progressive  nature  of  the  lesions 
in MMVD is not well understood, nor are the associations 
with progression, and therefore such a bold statement could 
not have been made. The findings of Chetboul et al. (2007) 
contradict  those  of  two  additional  mechanistic  studies. 
Ouellet et al. (2009) studied the effect of pimobendan versus 
control on selected echocardiographic parameters and found 
no significant changes between the two groups. In a small 
short-term experimental study, Kanno et al. (2007) found that 
pimobendan was associated with an improvement in mitral 
regurgitation (MR) and reduction in left atrial size. All three 
of these studies are within an experimental setting in the 
target species and are therefore considered grade 2 evidence. 
In  addition,  the  ability  of  echocardiography  to  assess 
myocardial function remains an area of debate (Bonagura & 
Schober 2009) and thus the results of experiments utilising 
echocardiography should be understood in that context.
Further  mechanistic  information  regarding  cardiovascular 
drugs has been obtained from invasive experimental studies. 
Devices implanted in the left atrium have been used to assess 
the effect of several drugs on left atrial pressure (Ishikawa 
et al. 2010; Suzuki, Fukushima, Ishikawa, Hamabe, Aytemiz, 
Huai-Che et al. 2011; Suzuki, Ishikawa, Hamabe, Aytemiz, 
Huai-Che, Fukushima et al. 2011; Suzuki et al. 2012). Drugs   
Page 2 of 7
TABLE 1: Grades of evidence in medical research trials.
Grade of evidence  Description of evidence grading 
Grade 1 (strongest) Evidence derived from one or more 
properly designed, prospective clinical 
trials in the target species 
Grade 2 Evidence derived from properly designed 
trials in the target species in a laboratory 
setting where disease is induced (for 
example, experimental induction of 
hypothyroidism)
Grade 3 Results of controlled retrospective 
studies, or cohort/case series studies, 
without randomisation 
Grade 4 (weakest)  Evidence obtained from studies in other 
species, opinion of experts, descriptive 
studies, case reports
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FIGURE  1:  Diagram  indicating  the  relationship  between  a  heart  failure  staging  system  and  natural 
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with  a  beneficial  effect  in  CHF  would  be  expected  to  be 
associated  with  a  reduction  in  left  atrial  pressure  (LAP), 
which would be associated with a concomitant decrease in 
pulmonary vein hydrostatic pressure. In these experimental 
studies,  increases  in  LAP  were  induced  experimentally 
by  transecting  the  chordae  tendinae.  Drugs  were  then   
administered  whilst  a  telemetric  device  in  the  left  atrium 
assessed  the  effect  on  LAP.  Utilising  this  technology, 
furosemide  (Suzuki,  Ishikawa,  Hamabe,  Aytemiz,  Huai-
Che,  Fukushima  et  al.  2011)  and  pimobendan  (Suzuki, 
Fukushima,  Ishikawa,  Hamabe,  Aytemiz,  Huai-Che  et  al. 
2011) were shown to exert a significant reduction in LAP in 
experimentally  induced  MMVD.  In  contrast,  ACEIs  were 
associated with a modest (Ishikawa et al. 2010) to no decrease 
in LAP (Suzuki et al. 2012). 
Given  the  disparity  in  the  results  and  inferences  of 
experimental  studies,  veterinary  practitioners  are  reliant 
on the outcome of clinical trials in natural disease settings 
to guide them in providing treatment recommendations to 
their clients.
Medical management of 
myxomatous mitral valve disease: 
An evidence-based approach
An ACE in the hole? The role of angiotensin-
converting enzyme inhibitors in the 
management of myxomatous mitral valve 
disease
Angiotensin-converting enzyme inhibitors in the 
treatment of congestive heart failure
Angiotensin-converting  enzyme  inhibitors  are  the  most 
intensively studied cardiac drugs in canine cardiology. The 
use of ACEI is rationalised based on the observation of the 
central role that the renin-angiotensin aldosterone-system 
(RAAS) plays in the pathogenesis of CHF (Benavente, Chue 
& Ferro 2010; Ma et al. 2010; Mochel et al. 2013). The RAAS 
system and its effects on blood pressure have been known 
since the 1940s, and the last 50 years have increased our 
understanding of the multiple deleterious effects of over-
exuberant RAAS activation in CHF (for an excellent review 
see Ma et al. 2010). In addition to increasing the workload of 
the heart by increasing preload and afterload, angiotensin 
and aldosterone have been implicated in the development 
of  fibrosis  and  hypertrophy  of  cardiac  muscle  (Bernay 
et al. 2010; Ma et al. 2010). Therefore, dysregulated RAAS 
activation  further  impairs  the  myocardium’s  ability  to 
cope with the increased demands placed on the heart by 
volume retention, vasoconstriction and counterproductive 
remodelling of the myocardium. Given the elucidation of 
this elegant physiological system, ACEIs seem an extremely 
attractive  option  to  attenuate  the  devastating  effects  of 
RAAS  activation.  Indeed,  the  development  of  ACEIs 
represents  a  triumph  in  the  integration  of  physiological 
understanding of a disease process and the development of 
a drug to attenuate it.
There  is  often  confusion  amongst  general  practitioners 
regarding the use of ACEIs in MMVD. It would be naïve of 
the veterinary profession to ignore the input of marketing 
from drug companies that have developed these drugs on 
the  prescribing  practice  within  the  profession.  Therefore, 
practitioners are reliant on the evidence to support or refute 
the role of ACEIs in MMVD. There can be no doubt that the 
addition of an ACEI to diuretic therapy in CHF attributable 
to MMVD improves the quality of life and life expectancy of 
the patient. Both the IMPROVE (Sisson 1995) and the COVE 
(Woodfield 1995) studies demonstrated an improvement in 
the heart failure and pulmonary oedema scores compared 
with the placebo group. Both studies were double-blinded 
studies and neither the investigator nor the client knew which 
group the patient was in. The end point of both studies was 
under a month (21 and 28 days respectively) and therefore 
long-term tolerability was not demonstrable. Following these 
two landmark studies, three additional ACEI trials which 
investigated the effect of ACEI versus placebo on the survival 
of patients with CHF ensued. The LIVE study (Ettinger et al. 
1998) demonstrated improved survival in the enalapril group 
(167 vs 87 days). This finding was supported by the BENCH 
study (BENCH Study Group 1999), which showed improved 
survival  of  patients  being  treated  with  benazepril  versus 
placebo (436 vs 151 days). A notable difference between these 
two studies was that the BENCH study included patients 
from modified New York Heart Association (NYHA) stages 
2 to 4, whilst the LIVE study included patients from NYHA 
stages 3 and 4. With the plethora of ACEIs on the market, 
which vary in price, it seems reasonable to assess possible 
differences  in  efficacy  between  currently  available  ACEIs. 
Veterinarians  frequently  ask  the  authors  if  there  is  a  real 
difference between these drugs, given the cost sensitivity of 
some of their clients; so what does the evidence say?
There is only one RCT in veterinary medicine that compares 
ACEIs in MMVD. The FIRST study showed no difference 
in the outcome in MMVD in patients treated with enalapril 
versus  imidapril  over  a  12-month  period  (Amberger 
et  al.  2004).  In  addition,  Hamlin  and  Nakayama  (1998) 
assessed  the  pharmacokinetics  of  five  common  ACEIs  in 
healthy beagles and showed that there were no significant 
differences  between  these  drugs,  with  the  exception  of 
captopril. Therefore, from an EBM point of view, there is 
no imperative to support the use of one of the commonly 
used  ACEIs  in  veterinary  medicine,  namely  enalapril 
and  benazepril,  over  the  other.  Notwithstanding  this 
observation, it bears mentioning that there is considerable 
debate  amongst  clinicians  regarding  this  issue,  as  many 
clinicians  report  improved  outcome  with  benazepril 
as  compared  with  enalapril.  Whilst  in  the  hierarchy  of 
evidence this is considered weak evidence, the input and 
experience  of  clinicians  cannot  be  ignored.  In  addition, 
studies in humans have shown that compliance decreases 
when medication requires administration more than once a 
day (Eisen, Miller & Woodward 1990). Therefore, an ACEI 
such as benazepril that is dosed once a day may improve 
compliance and therefore outcome in some cases. It is the 
authors’ opinion that a RCT comparison of benazepril and 
enalapril within the setting of CHF in MMVD as part of a 
polypharmacy treatment regimen is warranted, given the 
aggressive marketing of benazepril in the profession.Review Article
doi:10.4102/jsava.v85i1.1095 http://www.jsava.co.za
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Angiotensin-converting enzyme inhibitors in delaying the 
onset of congestive heart failure
The benefits of ACEIs in the treatment of CHF in MMVD 
are unassailable and supported by a number of high-quality 
studies. The same cannot be said for the role of ACEIs in 
delaying the onset of CHF in MMVD. It seems reasonable 
to speculate whether pharmacological interventions during 
the long preclinical period of MMVD may be of benefit to 
the  patients.  In  the  authors’  referral  clinic,  many  patients 
have been referred having being placed on an ACEI based on 
the presence of a murmur or a cough in a small-breed dog. 
Many veterinarians in the area still advocate the use of ACEIs 
in preclinical MR as a result of MMVD, and are adamant 
that these drugs are beneficial to their patients. Currently 
there is no express recommendation based on the literature 
available. It seems intuitively logical that accretion of RAAS 
peptides in worsening MMVD will reach a crucial tipping 
point  beyond  which  CHF  will  ensue.  Therefore,  it  seems 
logical that attenuation of RAAS will delay the onset of CHF 
in  MMVD.  This  is  the  rationale  behind  the  use  of  ACEIs 
in preclinical MMVD. Two large RCTs assessing the effect 
of enalapril versus placebo in delaying the onset of CHF, 
namely the SVEP (Kvart et al. 2002) and VETPROOF (Atkins 
et al. 2007) trials, failed to show a clear benefit of enalapril 
in  delaying  the  onset  of  CHF.  This  evidence  contradicts 
the findings of two retrospective trials assessing the effect 
of  benazepril  in  preclinical  MMVD  (Kitagawa  et  al.  1997; 
Pouchelon et al. 2008). The trial by Pouchelon et al. (2008) 
showed an impressive delay in onset of CHF in the treatment 
group. In the hierarchy of evidence, this study is a lower 
grade of evidence, given the fact that it was not randomised, 
prospective and blinded. It is therefore prone to bias and 
there are no clear indications as to why some subjects were 
treated and others were not. The divisions ensuing are seen in 
the lack of consensus over this issue in the ACVIM consensus 
statement regarding the medical management of MMVD.
Pimobendan: The perfect inotrope?
Prior to the availability of pimobendan, digoxin was typically 
used  to  provide  inotropic  support  to  the  heart.  Triple 
therapy  consisted  of  an  ACEI,  furosemide  and  digoxin. 
In  the  authors’  area  digoxin  is  still  widely  used  in  many 
practices because of the low cost of the drug. Pimobendan 
is a drug with a novel classification and its mechanism of 
action is understood to work by increasing the sensitivity of 
the myocardial contraction apparatus to calcium (Boswood 
2010; Boyle & Leech 2012). This purportedly improves the 
efficiency  of  contraction  without  increasing  myocardial 
workload,  because  it  does  not  increase  the  cytoplasmic 
calcium flux. A large part of cardiac adenosine triphosphate 
(ATP) is devoted to removing calcium from the cytoplasm 
via the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) 
pump (Klabunde 2011) and dysregulation of this mechanism 
has been implicated in the diastolic failure of the heart and 
indeed  part  of  the  whole  cascade  of  myocardial  failure 
(Sisson 2010). The fact that pimobendan has a dual action 
– it also functions as a phosphodiesterase (PDE) inhibitor – 
has been touted as an additional benefit, as PDE inactivates 
cyclic adenosine monophosphate (cAMP), which is involved 
in  the  up-regulation  of  proteins  responsible  for  arterial 
vasodilation (Boyle & Leech 2012). Because PDE functions by 
increasing cAMP, which in turn activates calcium channels 
leading to an influx of calcium in the myocardium, there has 
been debate as to whether the effect is a result of increased 
calcium  in  the  myocardium  or  calcium  sensitisation.  This 
may  seem  a  superfluous  academic  distinction,  but  it  is 
potentially  of  great  importance.  The  accretion  of  cellular 
calcium is associated with several key signalling cascades 
linked to apoptosis and necrosis. Intracellular calcium would 
be  expected  to  increase  ATP  turnover  (increasing  energy 
demands and generating free radicals), reduce the efficiency 
of lusitropy (the ability of the heart to relax) and activate 
apoptotic pathways (Klabunde 2011). Recently a consensus 
statement was released regarding the proposed mechanism 
of action of levosimendan, a drug similar to pimobendan, 
with  the  conclusion  that  the  drug  functions  mainly  by 
increasing the sensitivity of cardiac troponin C to calcium 
by  stabilising  the  saturation  of  the  receptor  by  calcium 
(Papp et al. 2012; Yokoshiki et al. 1997). In addition, some 
in vitro studies have demonstrated up-regulation of rescue 
pathways  by  levosimendan  in  the  case  of  cardiac  muscle 
ischaemia, inferring a cardiomyocyte protective role for the 
drug (for a review see Antoniades et al. 2007). Furthermore, 
pimobendan has been shown to enhance lusitropy in human 
hearts  through  the  phosphorylation  of  phospholamban 
(Bartel et al. 1996).
Notwithstanding the elucidation of this elegant mechanism, 
the performance of the drug in the clinic is ultimately the 
true  test  of  efficacy.  One  RCT  comparing  the  addition  of 
pimobendan versus benazepril in the treatment of MMVD 
has been performed (Häggström et al. 2008). In this study 
a  clear  benefit  of  pimobendan  was  seen  when  compared 
with  benazepril.  Pimobendan  has  also  been  shown  to 
improve  the  outcome  of  dilated  cardiomyopathy  (DCM) 
when compared with ACEI therapy and has recently been 
shown to delay the onset of clinical DCM in the Dobermann 
Pinscher  (Summerfield  et  al.  2012).  One  criticism  of  this 
RCT  has  been  that  monotherapy  drug  comparisons  (i.e. 
benazepril and furosemide vs pimobendan and furosemide) 
cannot  be  extrapolated  easily  to  the  clinic,  because  most 
practitioners  tend  to  treat  with  a  polytherapy  approach. 
It  must  be  understood,  however,  that  the  results  from 
studies are not always duplicated even between two studies 
with virtually identical study design, and that addition of 
therapeutic  interventions  causes  additional  variation  that 
cannot be accounted for. It is difficult to design blinded trials 
that assess clinical adjustments, or take the ‘best medicine’ 
approach. It is for this reason that trials have compared drugs 
with disparate mechanisms of action such as an ACEI and 
pimobendan. Having established the benefit of the addition 
of  these  drugs  in  a  RCT,  combinations  can  be  assessed 
in  future  trials.  Therefore,  whilst  pimobendan  has  been 
shown  to  improve  the  outcome  compared  with  an  ACEI, 
the ACVIM consensus statement recommends treatment of 
CHF in MMVD with both drugs (Atkins et al. 2009; Atkins 
& Häggström 2012). A trial is currently underway assessing 
the  efficacy  of  pimobendan  in  delaying  the  onset  of  CHF Review Article
doi:10.4102/jsava.v85i1.1095 http://www.jsava.co.za
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in  MMVD,  the  results  of  which  are  anticipated  in  2017 
(A. Boswood [Royal Veterinary College], pers. comm., 2011).
Spironolactone
In addition to the physiological effects of the RAAS system 
on  fluid  retention  and  vascular  tone,  angiotensin  and 
aldosterone have been implicated in remodelling of cardiac 
muscle, leading to fibrosis (Ma et al. 2010). Therefore, RAAS 
attenuation can be seen to have a dual action, reducing the 
workload of the heart and causing the remodelling of the 
heart muscle which compromises contractile function. The 
homeostatic regulation of the RAAS is unfortunately not as 
simple as it was once thought to be. Angiotensin I can be 
converted to angiotensin II (AT II) by alternate pathways, 
and thus there is a RAAS ‘escape’ mechanism, referred to 
as tissue or local RAAS (Benavente et al. 2010). Studies have 
shown that AT II levels are not consistently supressed with 
ACEI therapy and that urinary aldosterone (uALD) levels are 
not reduced (Atkins et al. 2012). One pharmacokinetic study 
investigated benazepril in healthy beagles with experimental 
RAAS  activation  and  demonstrated  a  decrease  in  plasma 
aldosterone but not uALD. The authors postulated that uALD 
may rise as a result of renal production of aldosterone, which 
does not enter circulation and therefore may be clinically less 
significant (Mochel et al. 2013).  
These  findings  have  occasioned  the  use  of  AT  II  receptor 
blockers  and  aldosterone  antagonists  to  circumvent  the 
deleterious  effects  of  RAAS  escape  in  human  medicine. 
The RALES study (Pitt et al. 1999) in humans investigating 
the effects of the addition of spironolactone demonstrated 
a  reduction  in  cardiac  events  when  spironolactone  was 
added  to  conventional  therapy.  These  findings  prompted 
a  veterinary  multicentre  RCT  assessing  the  addition  of 
spironolactone  to  conventional  therapy  in  CHF  (Bernay 
et al. 2010). The findings of the study were impressive and 
a  significant  reduction  in  cardiac  events  was  seen  in  the 
spironolactone  group.  Nevertheless,  the  findings  of  the 
study have not been universally accepted (see Kittleson & 
Bonagura 2010). Concerns have been raised regarding the 
study design of the project, based on the fact that the criteria 
for  confirming  heart  failure  were  not  clearly  defined.  It 
has been pointed out that the low numbers of patients that 
succumbed to heart failure or experienced events raises the 
concern that many of the patients were still in preclinical 
MMVD  (Kittleson  &  Bonagura  2010).  Therefore,  the  low 
number of events may have statistically skewed the results. 
The fact that the study made use of diverse researchers, from 
cardiologists to first opinion practices, has also been seen as 
a weakness in the study design (Kittleson & Bonagura 2010). 
These are all compelling arguments and it cannot be denied 
that the conclusions of a study are as strong as its design. 
Recently, Lefebvre et al. (2013) demonstrated the safety of 
spironolactone in the treatment of MMVD with early CHF. 
These authors showed that spironolactone was not associated 
with an increase in adverse events compared with placebo, 
and that there was a reduction in cardiac-related deaths in 
the spironolactone group. The study was randomised and 
controlled.  The  main  objective  of  this  study  was  to  show 
that spironolactone is safe and not associated with increased 
risk of renal disease. Whilst the authors did show improved 
survival in the spironolactone group, more than half of the 
cases in both groups were censored, with no criteria given. 
This  considerably  reduced  the  sizes  in  which  survival 
analysis could be performed. Thus the role of spironolactone 
remains controversial (Atkins et al. 2009; Atkins & Häggström 
2012; Häggström, Höglund & Borgarelli 2009). The benefits 
described in human studies when added to the veterinary 
trial may be seen to bolster the findings of the spironolactone 
study somewhat, but in the hierarchy of evidence studies in 
other species are seen as a weaker grade of evidence.
Current guidelines for medical management of 
myxomatous mitral valve disease
Having  understood  the  background  of  the  drugs  used 
in  MMVD  and  the  strengths  and  weaknesses  of  each, 
veterinarians  will  have  a  better  understanding  as  to  the 
intention of the ACVIM consensus statement and why there 
is incomplete consensus on some issues and not on others. 
The consensus statement regarding the medical management 
of  MMVD  has  provided  veterinary  practitioners  with  a 
valuable resource to guide them in the optimisation of the 
treatment  of  MMVD  (Atkins  et  al.  2009).  In  addition,  this 
document has proposed a standardised grading system for 
CHF which stratifies the MMVD population according to the 
severity of disease. This grading system is shown below, and 
ranges from stage A to D (Atkins et al. 2009):
Stage A: Predisposed to MMVD
Stage B: Mitral leak present
B1: No radiographic or echo evidence of remodelling
B2: Radiographic or echo evidence of remodelling
Stage C: CHF
Stage D: CHF resistant to OPTIMUM care. (p. 1143)
The consensus document supports the use of pimobendan, 
ACEIs and furosemide in the treatment of stages C and D. 
In addition, there is some evidence to support the addition 
of  spironolactone  in  stage  C,  but  there  was  not  complete 
consensus  regarding  this  recommendation  (Atkins  et  al. 
2009). The use of ACEIs in preclinical heart disease (stages 
B1 and B2) remains controversial. The most high-powered 
studies to date exploring the use of ACEIs in preclinical MR, 
namely the SVEP trial (Kvart et al. 2002) and the VETPROOF 
study (Atkins et al. 2007), failed to support the use of enalapril 
in preclinical MR. Two additional studies investigating the 
use of benazepril in preclinical MR suggested an improved 
outcome in the treated group (Kitagawa et al. 1997; Pouchelon 
et  al.  2008).  However,  these  studies  were  un-blinded  and 
not  randomised  and  thus  have  been  considered  to  be 
low-powered  studies,  warranting  a  prospective  placebo-
controlled trial to corroborate these findings.
Drugs that have been investigated recently but whose use 
remains unsupported include carvedilol (Gordon et al. 2012; 
Marcondes-Santos et al. 2007) and atorvastatin (Cunningham, 
Rush & Freeman 2013). These drugs have been shown to be Review Article
doi:10.4102/jsava.v85i1.1095 http://www.jsava.co.za
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safe, but have not demonstrated any quantifiable beneficial 
results. Practitioners are cautioned against using medication 
for which good evidence does not exist, given the current 
cost  of  medication  and  the  inclination  of  some  clients  to 
pursue legal action against medical professionals who do not 
subscribe to codes of practice. 
Finally, mitral valve replacement is an exciting new area of 
investigation and some promising results have been observed 
(Uechi 2012). This remains an unattainable ideal for most 
practitioners and pet owners alike; however, as technology 
advances,  these  techniques  will  become  increasingly 
available, and may revolutionise the way in which MMVD 
is managed.
Furosemide and newer loop diuretics
Intractable  congestion  and  oedema  is  a  common  feature 
of clinically severe CHF as a result of MMVD (Häggström 
et  al.  2009;  Peddle  et  al.  2012).  These  haemodynamic 
consequences  accrue  as  a  result  of  volume  retention  and 
concomitant  increases  in  capillary  hydrostatic  pressures 
(Klabunde  2011).  The  vascular  beds  of  the  lungs  are 
particularly  susceptible  to  increased  hydrostatic  pressure 
(Klabunde 2011). Drugs that are able to reduce the blood 
volume are therefore highly effective in reducing pulmonary 
congestion and oedema. Furosemide is a loop diuretic that 
inhibits  the  Na+,  K+,  Cl-  symporter  in  the  ascending  loop 
of  Henle  (Peddle  et  al.  2012).  Furosemide  is  an  efficient 
diuretic that is associated with predictable diuresis and is 
highly  effective  at  treating  the  congestion  associated  with 
CHF (Peddle et al. 2012). There are surprisingly few trials 
investigating  the  efficacy  of  furosemide  in  the  veterinary 
literature. A PubMed search failed to return any placebo-
controlled RCTs on furosemide in dogs. Notwithstanding the 
paucity of literature supporting its use, it cannot be denied 
that furosemide is highly effective in ameliorating the clinical 
signs of congestion. A recent study investigated the use of 
torsemide  (a  loop  diuretic),  which  was  occasioned  by  the 
observation of superior efficacy in the treatment of human 
CHF  compared  with  furosemide.  The  study  showed  that 
both these diuretics were effective in controlling congestion 
(Peddle et al. 2012).
Conclusion
The current body of evidence serves as a valuable guideline 
to  guide  veterinarians  in  the  medical  management  of 
MMVD.  Future  research  is  needed  to  fully  elucidate  the 
role  of  spironolactone  in  the  management  of  MMVD. 
Veterinarians  should  understand  and  apply  EBM  when 
making  recommendations  to  clients  in  the  treatment  of 
MMVD.
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